Evidence map›Paper›PMID 37164674›Full record

ArticleInternal medicine (Tokyo, Japan)2023

Primary Retroperitoneal Mucinous Cystadenocarcinoma during Long-term Administration of Infliximab for the Treatment of Crohn's Disease.

Yoshiki Morihisa, Shunji Urai, Hiroyoshi Iwagami, Masayuki Shimoyama, Shinya Ogino, Tomoko Terashita, Hiroki Morimura, Takuji Akamatsu, Yoshito Uenoyama, Yukitaka Yamashita

Open access · diamondAbstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Internal medicine (Tokyo, Japan), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
1.6field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 5 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 1 institution in 1 country.

Yoshiki MorihisaDepartment of Gastroenterology and Hepatology, Japanese Red Cross Wakayama Medical Center, Japan.
Shunji UraiDepartment of Gastroenterology and Hepatology, Japanese Red Cross Wakayama Medical Center, Japan.
Hiroyoshi IwagamiDepartment of Gastroenterology and Hepatology, Japanese Red Cross Wakayama Medical Center, Japan.
Masayuki ShimoyamaDepartment of Gastroenterology and Hepatology, Japanese Red Cross Wakayama Medical Center, Japan.
Shinya OginoDepartment of Gastroenterology and Hepatology, Japanese Red Cross Wakayama Medical Center, Japan.
Tomoko TerashitaDepartment of Gastroenterology and Hepatology, Japanese Red Cross Wakayama Medical Center, Japan.
Hiroki MorimuraDepartment of Gastroenterology and Hepatology, Japanese Red Cross Wakayama Medical Center, Japan.
Takuji AkamatsuDepartment of Gastroenterology and Hepatology, Japanese Red Cross Wakayama Medical Center, Japan.
Yoshito UenoyamaDepartment of Gastroenterology and Hepatology, Japanese Red Cross Wakayama Medical Center, Japan.
Yukitaka YamashitaDepartment of Gastroenterology and Hepatology, Japanese Red Cross Wakayama Medical Center, Japan.
Japanese Red Cross Society Wakayama Medical Center · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

We herein report a rare case of primary retroperitoneal mucinous cystadenocarcinoma (PRMC) in a 60-year-old man. The patient, who had been treated with infliximab for Crohn's disease of the colon for 13 years, was referred to our hospital for lower back pain. Contrast-enhanced computed tomography (CT) and magnetic resonance imaging revealed multiple cystic lesions in the right retroperitoneum, the calcification of the cyst, and bone lesions. Bone and CT-assisted biopsies of the retroperitoneal lesions revealed poorly differentiated adenocarcinoma. The patient was diagnosed with PRMC with bone metastases using immunohistochemical staining and positron emission tomography/CT.

Indexed as

Crohn DiseaseCystadenocarcinoma, MucinousRetroperitoneal NeoplasmsHumansInfliximabMaleMiddle AgedTomography, X-Ray ComputedInfliximabCrohn's diseaseinfliximabmultiple cystic lesionsprimary retroperitoneal mucinous cystadenocarcinoma

Identifiers

PMID37164674
PMCPMC10781556
OpenAlexW4376132911

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.